
zzso therapy of zzso kidney cancer has undergone dramatic changes over the past zzso One reason for this is our increasing knowledge of different zzso zzso and associated genetic zzso Furthermore, zzso pathways have been identified to be relevant for zzso progression and therapeutic zzso Until some years ago, systemic therapy for kidney cancer consisted of zzso In this review, new drugs for the treatment of zzso kidney cancer are zzso These drugs predominantly interact the zzso zzso and zzso zzso zzso Four drugs have been studied in phase III trials and were (or will soon be) approved for treatment of zzso kidney zzso Additionally, many drugs are currently being tested in phase I and phase II zzso At present, the following scenarios have an impact on therapy zzso different zzso groups, zzso and zzso therapy, combination therapies and the impact of different zzso zzso 

